Takeda, Pfizer, and ASKA Pharmaceutical Conclude Agreement on Seltouch
Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and ASKA Pharmaceutical Co., Ltd have reached an agreement to conclude their contracts regarding the product Seltouch (felbinac). Effective September 30, 2014, the distribution and marketing activities for both the poultice formulation and the tape formulation of Pfizer’s transdermal absorption-type analgesic and anti-inflammatory agent Seltouch (Seltouch PAP 70, Seltouch PAP 140, and Seltouch TAPE 70) by Takeda and ASKA will be concluded. Effective October 1, 2014, Pfizer will conduct the distribution and marketing activities for this product.
Seltouch was launched in 1993 with Pfizer and Takeda conducting distribution and marketing activities for the product. In July 2009, Pfizer and ASKA signed an agreement related to the commercialization rights of the poultice formulation of Seltouch while at the same time, ASKA and Takeda signed an agreement in which the distribution and marketing activities for that formulation of Seltouch were entrusted to Takeda. In 2011, a tape formulation was launched, and Pfizer entrusted the distribution and marketing activities for the tape formulation to Takeda. Presently, due to changes in the business environment surrounding all three companies, it was decided in agreement among all three companies to conclude these agreements in order to maximize the product value of Seltouch.
Source: Takeda Pharmaceutical